Impact of oral anticoagulation on inhospital mortality of patients with hip fracture - Analysis of nationwide hospitalization data.


Journal

Injury
ISSN: 1879-0267
Titre abrégé: Injury
Pays: Netherlands
ID NLM: 0226040

Informations de publication

Date de publication:
Jul 2023
Historique:
received: 26 08 2022
revised: 26 04 2023
accepted: 13 05 2023
medline: 12 6 2023
pubmed: 29 5 2023
entrez: 28 5 2023
Statut: ppublish

Résumé

Oral anticoagulation (OAC) may have an impact on mortality in cases hospitalized for hip fracture (HF). We studied nationwide time trends of OAC prescriptions and compared time trends of inhospital mortality of HF cases with and without OAC in Germany DESIGN: Retrospective cohort study SETTING: Nationwide German hospitalization, Diagnosis-Related Groups Statistic PATIENTS/PARTICIPANTS: All hospital admissions for HF 60 years and older in the years 2006 through 2020. Additional diagnosis with a personal history of long-term use of anticoagulants (ICD code Z92.1). Inhospital mortality RESULTS: Cases hospitalized for HF 60 years and older increased by 29.5%. In 2006, 5.6% had a documented history of long-term use of OACs. This proportion rose to 20.1% in 2020. Age-standardized hospitalization mortality in HF cases without long-term use of OACs in males decreased steadily from 8.6% (95% confidence intervals 8.2 - 8.9) in 2006 to 6.6% (6.3 - 6.9) in 2020 and in females from 5.2% (5.0 - 5.3) to 3.9% (3.7 - 4.0). Mortality of HF cases with long-term use of OACs remained unchanged: males 7.0% (5.7 - 8.2) in 2006 and 7.3% (6.7 - 7.8) in 2020, females 4.8% (4.1 - 5.4) and 5.0% (4.7 - 5.3). Inhospital mortality of HF cases with and without long-term OAC show different trends. In HF cases without OAC, mortality decreased from 2006 to 2020. In cases with OAC such a decrease could not be observed.

Identifiants

pubmed: 37246114
pii: S0020-1383(23)00494-1
doi: 10.1016/j.injury.2023.05.060
pii:
doi:

Substances chimiques

Anticoagulants 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

110829

Informations de copyright

Copyright © 2023 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors have no relevant financial or non-financial interests to disclose.

Auteurs

Kathrin Feller (K)

Clinic for Plastic Surgery, HELIOS Klinik Krefeld, Germany.

Nabil Abdel-Jalil (N)

Emergency Department, HELIOS Klinik Duisburg, Germany.

Christian Blockhaus (C)

Clinic of Cardiology, HELIOS Klinik Krefeld, Germany; University of Witten/Herdecke, Witten- Herdecke, Germany.

Knut Kröger (K)

Clinic of Vascular Medicine, HELIOS Klinik Krefeld, Germany. Electronic address: knut.kroeger@helios-gesundheit.de.

Bernd Kowall (B)

Institute for Medical Informatics, Biometry and Epidemiology, University Hospital Essen, Germany.

Andreas Stang (A)

Institute for Medical Informatics, Biometry and Epidemiology, University Hospital Essen, Germany; Department of Epidemiology, Boston University School of Public Health, 715 Albany St, Boston, MA, 02118, United States of America.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH